The protocol to control unstable tachycardia with landiolol in septic patients

The protocol to control unstable tachycardia with landiolol in septic patients - T-START(Tsukuba-septic tachycardia therapy trial)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026753

Enrollment

Registered

2017-03-29

Start date

2017-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Landiolol hydrochloride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: probable sepsis (probable infection with positive qSOFA) narrow-QRS tachycardia over 100 bpm in heart rate

Exclusion criteria

Exclusion criteria: cardiogenic shock diabetic keto-acidosis or mebolic acidosis high grade atrial-vetricular block, sick sinus syndrome right ventricular failure with pulmonary hypertension allergy against landiolol severe heart failure severe bronchial asthma pregnant or lactating patients patients under 100 bpm in heart rate pheochromocytoma without any therapy

Design outcomes

Primary

Measure	Time frame
The prevention of organ failure	—

Secondary

Measure	Time frame
survival rate for 30 and 60 days, Duration of intensive care unit and hospital stay etc.	—

Countries

Japan

Contacts

Public ContactNobutake Shimojo

University of Tsukuba Faculty of Medicine

nkshimojo@md.tsukuba.ac.jp0298533210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026